ClinicalTrials.gg
CompletedNCT05745207Updated Oct 2, 2024

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

A Phase 1 interventional study of E2086 and Placebo in Healthy Volunteers, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoking, male or female, age greater than or equal to (>=) 18 years to less than or equal to (\<=) 55 years old (greater than [>] 65 years old for Part B) at the time of . To be considered non-smokers, participants must have discontinued smoking for at least 4 weeks before dosing.
  2. Reports regular bedtime, defined as the time the participant attempts to sleep, between 21:00 and midnight, based on sleep diary data from the Screening Period.
  3. Reports regular waketime, defined as the time the participant gets out of bed for the day, between 05:00 and 10:00, based on sleep diary data from the Screening Period.
  4. (BMI) >=18 to less than (\<) 30 kilogram per square meter (kg/m\^2) at Screening.

Exclusion criteria

Exclusion Criteria:

  1. illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
  2. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the dose of study drug.
  3. All females who are of :

    • All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  4. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective throughout the study period or for 28 days after study drug discontinuation). No sperm donation is allowed during the study period or for 90 days after study drug discontinuation
  5. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing (example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system)
  6. Any history of a congenital abnormality in metabolism at Screening
  7. Any history of seizure, epilepsy, or non-epileptic seizures
  8. Any history of surgery that may affect PK profiles of E2086 (example, hepatectomy, nephrotomy, digestive organ resection) at Screening
  9. Any clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, finding, or laboratory test results that require medical treatment at Screening or Baseline
  10. Liver function test values outside of the normal laboratory defined range at Screening or Baseline.
  11. Any history of liver disease.
  12. Known history of liver function test values outside of the normal laboratory defined range within the last 6 months.
  13. Evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease, sleep disorders) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
  14. A prolonged /QTc interval (QTc >450 milliseconds [ms]) demonstrated on ECG at Screening or Baseline (based on average of triplicate ECGs). A history of risk factors for torsade de pointes (example, heart failure, hypokalemia, family history of long QT Syndrome) or the use of concomitant medications that prolonged the QT/QTc interval
  15. Left bundle branch block at Screening or Baseline
  16. Persistent systolic BP >130 or \<100 millimeters of mercury (mmHg) or diastolic BP >85 or \<50 mmHg at Screening or Baseline (based on BP measured on at least 3 occasions over 2 weeks)
  17. Persistent heart rate (HR) less than 50 beats/min or more than 100 beats/min at Screening or Baseline (based on HR measured on at least 3 occasions over 2 weeks)
  18. History of myocardial infarction, ischemic heart disease, or cardiac failure at Screening
  19. History of clinically significant arrhythmia or uncontrolled arrhythmia
  20. Known history of clinically significant drug allergy at Screening or Baseline
  21. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline
  22. Known to be (HIV) positive at Screening
  23. Active or chronic viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening
  24. Active Epstein Barr virus (EBV) as demonstrated by positive serology at Screening
  25. History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive drug test or alcohol test at Screening or Baseline
  26. Intake of caffeinated beverages or food within 72 hours before dosing
  27. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing
  28. Any lifetime history of suicidal ideation or any lifetime history of suicidal behaviour as indicated by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  29. Any lifetime history of psychiatric disease (including but not limited to depression or other mood disorders, bipolar disorder, psychotic disorders, including schizophrenia, panic attacks, anxiety disorders). The absence of a history of psychiatric disease should be documented by a checklist in the eCRF.
  30. Any current psychiatric symptoms as indicated by a standard screening tool ( [DSM-5] Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult)
  31. Participants who's 1st degree (blood) relatives have lifetime diagnosis of bipolar type I disorder or a psychotic disorder.
  32. Use of prescription drugs within 4 weeks before dosing
  33. Intake of over the counter (OTC) medications within 2 weeks before dosing
  34. Currently enrolled in another clinical study or used any drug or device within 30 days or 5 half-lives, whichever is longer, preceding
  35. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
  36. Epileptiform discharges on screening EEG
  37. History of formally diagnosed moderate to severe obstructive sleep apnea, current use of continuous positive airway pressure, or symptomatic restless legs syndrome.
  38. Exposure within the last 14 days to an individual with confirmed or probable COVID-19 or symptoms within the last 14 days that are on the most recent Centers for Disease Control and Prevention (CDC) list of COVID symptoms or any other reason to consider the participant at potential risk for COVID-19 infection.
  39. Exposure to any biologic drug within 90 days or at least 5 half-lives (whichever is longer), or within 4 weeks for vaccines, before Screening, with the exception of flu (7 days before dosing) and COVID-19 vaccination (14 days before dosing until after the Follow-up visit).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Part A, Cohort 1: E2086 1 mg or Placebo

    Participants will receive 1 milligram (mg) (2\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 2: E2086 2.5 mg or Placebo

    Participants will receive 2.5 mg (5\*0.5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 3: E2086 5 mg or Placebo

    Participants will receive 5 mg (1\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 4: E2086 10 mg or Placebo

    Participants will receive 10 mg (2\*5 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 5: E2086 25 mg or Placebo

    Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 6: E2086 50 mg or Placebo

    Participants will receive 50 mg (2\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part A, Cohort 7: E2086 100 mg or Placebo

    Participants will receive 100 mg (4\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

  • Experimental
    Part B, Cohort 8: E2086 25 mg or Placebo

    Participants will receive 25 mg (1\*25 mg) E2086 or E2086 matched placebo, tablets, orally, once on Day 1.

    Drug: E2086 · Drug: Placebo

Interventions

  • DrugE2086

    E2086 tablets.

  • DrugPlacebo

    E2086 matched placebo tablets.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From Screening up to 10 days

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: From Screening up to 10 days

  3. Number of Participants With Clinically Significant Abnormal Laboratory Values

    Time frame: From Screening up to 10 days

  4. Number of Participants With Clinically Significant Abnormal Vital Signs Values

    Time frame: From Screening up to 10 days

  5. Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings

    Time frame: From Screening up to 10 days

  6. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Time frame: From Screening up to 10 days

  7. Number of Participants With Clinically Significant Abnormal Physical Examination Findings

    Time frame: From Screening up to 10 days

  8. Number of Participants With Clinically Significant Abnormal Neurological Examination Findings

    Time frame: From Screening up to 10 days

  9. Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) Findings

    Time frame: Baseline, Days 1 and 2

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  2. Tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  3. AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 24 hours post-dose

  4. AUC(0-t): Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  5. AUC(0-72h): Area Under the Plasma Concentration-time Curve From Time Zero to 72 hours Post-dose for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 72 hours post-dose

  6. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  7. t1/2: Terminal Elimination Phase Half-life for E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  8. CL/F: Apparent Total Clearance for E2086

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  9. Vz/F: Apparent Volume of Distribution at Terminal Phase for E2086

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  10. MRp: Ratio of Plasma AUC(0-inf) of Metabolite to E2082, Corrected for Molecular Weights

    Time frame: Day 1: Pre-dose (0 hour) up to 216 hours post-dose

  11. Mean Change in Subjective Sleep Onset Latency (sSOL)

    sSOL is a participant-reported estimate of the amount of time (in minutes) it took the participant to fall asleep the prior evening.

    Time frame: Screening up to Study Day 7

  12. Ae: Cumulative Amount of E2086 and its Metabolites Excreted in Urine

    Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose

  13. CLR: Renal Clearance of E2086 and its Metabolites

    Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose

  14. Fe: Percent (%) of E2086 and its Metabolites Excreted in Urine

    Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose

  15. MRU: Ratio of Ae Urine Concentration of Metabolite to E2082, Corrected for Molecular Weights

    Time frame: Day 1: Pre-dose (0 hour) up to 120 hours post-dose

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jan 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Feb 20, 2023
Primary completionActual
Jan 18, 2024
CompletionActual
Jan 18, 2024
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745207
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Feb 20, 2023
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024
Last update
Oct 2, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledasorexton

Start the discussion